Loading peptide profile…
Loading peptide profile…
Longevity Category
THE IMMUNE BALANCER
Glu-Asp-Pro Peptide
Crystagen is the tripeptide glutamate-aspartate-proline. Research includes aging spleen experiments and developer reports of use in patients with immune abnormalities, without establishing a reliable clinical benefit. It is not FDA approved.
Aging individuals with weakened immunity · People recovering from illness or chemotherapy · Those with chronic infections · Athletes under high training stress
Based on what vendors sell, not a recommendation.
Injection
Sold as vials by 6 vendors
By mouth
Not sold by vendors we track
Nasal spray
Not sold by vendors we track
Not FDA approved, research use onlyHow we review these guides4 research sources
The cited study reported B-cell activity with Crystagen but no change in cell renewal in the aging spleen. Effects of other peptides are separate findings.
A review and a commercial report describe changes in immune markers. Incomplete methods and developer-linked reporting prevent a firm clinical conclusion.
Reduces pro-inflammatory cytokines while boosting protective ones
No. This profile records Crystagen as not FDA approved and for research use only. Review the regulatory and source details on this page for the current context.
This guide links to 4 curated or current research sources. Inspect the research section and the citations beneath the research answers for their supporting sources.
Review the Crystagen research sourcesWe don't list specific side effects for Crystagen.
Crystagen has an editorial safety grade of A (Excellent Safety). Developer reports describe human use but do not provide a reliable systematic safety assessment. Laboratory immune-cell findings cannot establish clinical adverse effects or long-term safety. Safety depends on dose, sourcing, health history and medical supervision, so this page does not call it safe for personal use.
According to the research, Crystagen is one of four short peptides (with Vilon, Timogen and R-1) that possess various immunoprotective effects in the spleen during its ageing. The same work reports that Crystagen activates B-cells of the immune system. However, the peptide was found not to cause cell renewal in the spleen as it ages.
Crystagen is reported to activate B-cells of the immune system. The study type for this finding is recorded only as "other", and no species applies to it. The same passage notes that the peptide does not cause cell renewal in the spleen as it ages.
In-stock prices from 6 vendors, checked Nov 10, 2026.
Market evidence
We found certificates from a few of the Crystagen vendors we track. Based on the certificates our crawler found; vendors may publish more than we index. Research on this page describes the molecule. Vendor certificates concern particular market samples or batches; they do not change the research evidence or establish clinical safety, sterility, or suitability for use.
The clinic network
Request a free connection to a peptide clinic, by telehealth or in person. A licensed clinician decides whether any treatment is right for you. What peptide therapy involves
Immune-modulating thymus peptide approved abroad but not in the U.S.
from $2.30/mg · 179 vendorsNº 004 / 006Tetrapeptide that loosened chromatin in cultured elderly cells
from $1.38/mg · 24 vendorsNº 001 / 006An animal bronchial peptide mixture in developer reports
Full profileNº 002 / 006Thymagen is a thymus-derived bioregulator peptide that helps restore immune balance. It promotes T-cell differentiation, modulates inflammatory responses, and enhances...
from $2.05/mg · 20 vendorsNº 003 / 006Zinc-dependent thymus peptide, untested as a therapy in modern trials
from $1.85/mg · 17 vendorsNº 005 / 006An animal thymus peptide mixture in developer reports
Full profileNº 006 / 006